Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study

Miikka Lehtonen, Jorma Sormunen, Marie Hjälm-Eriksson, Camilla Thellenberg-Karlsson, Teppo Huttunen, Claes Ginman, Pirkko Liisa Kellokumpu-Lehtinen

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Background/Aim: The goal of this study was to investigate whether health-related quality of life (HRQoL) was affected in patients with high- or intermediate-risk localized prostate cancer treated with docetaxel following radiation therapy (RT). Patients and Methods: A total of 376 patients treated with RT and androgen deprivation were randomized to receive 6 cycles of docetaxel 75 mg/m2 (N=188, Arm A) or surveillance (N=188, Arm B). FACT-P HRQoL questionnaires were gathered at baseline, six months and 1, 2 and 4 years after randomization. The data were analysed using analysis of covariance. Results: FACT-P scores decreased in Arm A at the end of treatment and remained unchanged in Arm B (p<0.0001). The HRQoL scores in Arm A matched Arm B in the 1-year follow-up (p=0.0528) and remained similar in further follow-up. Conclusion: Docetaxel transiently decreased HRQoL during chemotherapy but not after treatment for up to four years of follow-up.

Original languageEnglish
Pages (from-to)87-92
Number of pages6
JournalAnticancer Research
Volume42
Issue number1
Early online dateDec 2021
DOIs
Publication statusPublished - 2022
Publication typeA1 Journal article-refereed

Keywords

  • Docetaxel
  • Prostate cancer
  • Quality of life
  • Radiotherapy

Publication forum classification

  • Publication forum level 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Health-related Quality of Life in Intermediate- or High-risk Patients Treated with Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study'. Together they form a unique fingerprint.

Cite this